ALX Oncology’s (ALXO) “Overweight” Rating Reaffirmed at Cantor Fitzgerald

ALX Oncology (NASDAQ:ALXO)‘s stock had its “overweight” rating reissued by investment analysts at Cantor Fitzgerald in a note issued to investors on Wednesday,Benzinga reports.

Separately, HC Wainwright restated a “buy” rating and set a $25.00 price objective on shares of ALX Oncology in a research report on Wednesday. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, ALX Oncology presently has a consensus rating of “Moderate Buy” and an average target price of $10.67.

ALX Oncology Stock Performance

Shares of NASDAQ:ALXO opened at $1.79 on Wednesday. The company’s 50 day simple moving average is $1.49 and its 200 day simple moving average is $3.40. The company has a debt-to-equity ratio of 0.07, a current ratio of 4.82 and a quick ratio of 4.82. ALX Oncology has a 1 year low of $1.19 and a 1 year high of $17.83. The stock has a market capitalization of $94.41 million, a price-to-earnings ratio of -0.60 and a beta of 1.04.

Insider Activity

In other ALX Oncology news, Director Rekha Hemrajani purchased 30,000 shares of the business’s stock in a transaction dated Monday, December 2nd. The shares were bought at an average price of $1.55 per share, for a total transaction of $46,500.00. Following the completion of the acquisition, the director now owns 33,000 shares in the company, valued at approximately $51,150. This trade represents a 1,000.00 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 33.40% of the company’s stock.

Institutional Investors Weigh In On ALX Oncology

A number of institutional investors have recently made changes to their positions in ALXO. Marshall Wace LLP grew its holdings in ALX Oncology by 423.0% during the 2nd quarter. Marshall Wace LLP now owns 635,679 shares of the company’s stock worth $3,833,000 after acquiring an additional 514,133 shares during the period. Privium Fund Management B.V. increased its holdings in ALX Oncology by 28.2% in the third quarter. Privium Fund Management B.V. now owns 509,059 shares of the company’s stock worth $926,000 after purchasing an additional 112,093 shares in the last quarter. Renaissance Technologies LLC lifted its stake in ALX Oncology by 87.2% in the second quarter. Renaissance Technologies LLC now owns 438,200 shares of the company’s stock valued at $2,642,000 after buying an additional 204,100 shares during the period. XTX Topco Ltd bought a new position in shares of ALX Oncology during the 3rd quarter worth approximately $578,000. Finally, Point72 Asset Management L.P. acquired a new stake in shares of ALX Oncology during the 2nd quarter worth approximately $1,834,000. Institutional investors own 97.97% of the company’s stock.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.